(PharmaNewsWire.Com, May 16, 2017 ) Actinic Keratosis Market Insights, Epidemiology and Market Forecast-2023-7MM report provides an overview of the disease and global market size of the Actinic Keratosis for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Actinic Keratosis from 2013-2023.
Actinic Keratosis (AK) commonly known as a solar keratosis is a precancerous crusty lesion caused by damage from exposure to ultraviolet (UV) radiation. It is considered a pre-cancer condition if left untreated could develop into a skin cancer, most often squamous cell carcinoma (SCC). AKs appear on areas which are most commonly exposed to sun such as the face, scalp, shoulders, neck, the back of the hands and forearms, etc.
According to DelveInsight, the market size for Actinic Keratosis in 7 MM is estimated to be USD XX Million by 2023 at a CAGR of 2.5% for the forecast period i.e., 2013-2023. Market size covered in our report, is based only upon the topical therapies approved for Actinic Keratosis.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope - The report will help in developing business strategies by understanding the trends shaping and driving the Actinic Keratosis market. - Organize sales and marketing efforts by identifying the best opportunities for Actinic Keratosis in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan. - To understand the future market competition of Actinic Keratosis therapies in the 7MM and Insightful review of the key market drivers and barriers. - The report provides historical as well as forecasted epidemiology of Actinic Keratosis in the 7MM. - To understand the regulatory scenario in major markets. - The Report also covers the detailed historical and forecasted Actinic Keratosis market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
Report Introduction 2 Actinic Keratosis Market Overview at a Glance 9 7 MM Market Size of Actinic Keratosis (2013-2023) 9 Total Market Share Distribution of Actinic Keratosis for 7 MM in 2016 10 Total Market Share Distribution of Actinic Keratosis for 7 MM in 2023 10 Overview 11 Signs and symptoms 11 Risk Factors 11 Pathophysiology 13 Diagnosis 15 Histopathology 15 Epidemiology and Patient Population 16 United States 16 Europe 18 Germany 19 France 20 United Kingdom 21 Italy 22 Spain 24 Japan 26 Treatment Algorithm 28 Lesion-Directed Therapies: 29 Field-Directed Therapies 29 Photodynamic therapy 30 Marketed Drugs 32 Aldara: Valeant Pharmaceuticals 32 Drug Description 32 Mechanism of Action 32 Regulatory Milestones 32 Advantages & Disadvantages 33 Safety and Efficacy of Aldara 33 Product Profile 33 Zyclara: Valeant Pharmaceuticals 34 Drug Description 34 Mechanism of Action 34 Regulatory Milestones 34 Advantages & Disadvantages 35 Safety and Efficacy of Zyclara 35 Product Profile 36 ......
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
